Patients had a diagnosis of nonmyeloid malignancy with ≥ 8 weeks of planned chemotherapy, age ≥ 18 years, and anemia (hemoglobin ≤ 11 g/dL). Patients were randomly assigned 1:1 to DA 200 μg every two ...

Patient characteristics are summarized in Table 1 . A total of 14 patients received at least one dose of darbepoetin alfa, and the 12 who received more than one dose were assessable. Eleven ...

Darbepoetin was well tolerated and conveniently coordinated with cyclic chemotherapy. Ten patients maintained a hemoglobin concentration of ≥11 g/dL for at least two treatment periods.

Hyporesponsiveness to erythropoiesis-stimulating agents (ESAs), whether defined as lack of hemoglobin response to typical ESA doses or need for higher ESA doses to reach hemoglobi ...

Darbepoetin Alfa is a medication that helps the body produce more red blood cells to treat anaemia caused by kidney failure or chemotherapy. Sheikh Saqer Bin Humaid Al Qasimi, Chairman of the Board, ...

and work in a different way to ESAs like epoetin alfa and darbepoetin alfa, which stimulate the production of more blood cells in in the bone marrow. In addition to the added convenience of oral ...

He discusses the role of darbepoetin alfa (Cresp) in improving and maintaining hemoglobin levels, enhancing patient tolerance to therapy, and ensuring continuity of cancer treatment. The case involves ...

Not recommended in patients with cirrhosis or active, acute liver disease. Worsening of hypertension was reported in 14% of VAFSEO and 17% of darbepoetin alfa patients. Serious worsening of ...

Recent advances in defining low- and intermediate-risk myelodysplastic syndromes (MDSs) have emphasized the critical role of molecular characterization using next-generation sequencing (NGS).

According to the rumor mill and also via official sources, the second-generation Alfa Romeo Stelvio will get its five minutes of official red-carpet glory during the second half of the year.